Quick Answer
Immunovant, Inc. reported Shares Outstanding of 170.11 million shares for fiscal year 2025.
Immunovant, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 170.11M | +16.8% |
| 2024 | 145.58M | +11.7% |
| 2023 | 130.33M | +11.9% |
| 2022 | 116.48M | +18.9% |
| 2021 | 97.97M | +79.3% |
| 2020 | 54.66M | +41.6% |
| 2019 | 38.59M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | 203.32M | +38.1% | +16.5% |
| September 30, 2025 | 174.53M | +19.1% | +2.0% |
| June 30, 2025 | 171.07M | +17.0% | +0.6% |
| March 31, 2025 | 170.11M | +16.8% | +15.6% |
| December 31, 2024 | 147.20M | +1.5% | +0.4% |
| September 30, 2024 | 146.57M | +11.5% | +0.3% |
| June 30, 2024 | 146.20M | +12.0% | +0.4% |
| March 31, 2024 | 145.58M | +11.7% | +0.3% |
- Immunovant, Inc. showed an increase of +16.8% in Shares Outstanding compared to the prior fiscal year.
- Over the 2019–2025 period, Immunovant, Inc.’s shares outstanding has grown by 340.8% (from 38.59 million shares to 170.11 million shares).
- The most recent figure is from Immunovant, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on May 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: